What is the normal rate of bone remodeling?

Bone

Volumn 35, Issue 1, 2004, Pages 1-3

  Parfitt, A M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY WEIGHT; BONE AGE; BONE MASS; BONE MINERAL; BONE REMODELING; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CANCELLOUS BONE; FRAGILITY FRACTURE; HUMAN; OSTEOCYTE; OSTEOPENIA; REFERENCE VALUE; SHORT SURVEY;

EID: 2942737029     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.03.022     Document Type: Editorial

References (29)

1. Murphy E.J. The normal, and the perils of the sylleptic argument. Perspect. Biol. Med. 1972 (Summer);566-582
2. Parfitt A.M. Calcium homeostasis. Mundy G.R., Martin T.J. Handbook of Experimental Pharmacology. Physiology and Pharmacology of Bone. vol. 107:1993;1-65 Springer-Verlag, Heidelberg
3. Grasbeck R. Reference values, why and how. Scand. J. Clin. Lab. Invest. Suppl. 201:1990;45-53
4. Heaney R.P. Editorial: Vitamin D, nutritional deficiency, and the medical paradigm. J. Clin. Endocrinol. 88:2003;5107-5108
5. Heaney R.P. Is the paradigm shifting? Bone. 33:2003;457-465
6. Perzigian A.J. Osteoporotic bone loss in two prehistoric Indian populations. Am. J. Phys. Anthropol. 39:1973;87-95
7. Parfitt A.M. Skeletal heterogeneity and the purposes of bone remodeling: implications for the understanding of osteoporosis. Marcus R., Feldman D., Kelsey J. Osteoporosis. second ed. 2001;433-447 Academic Press, San Diego
8. Qiu S., Palnitkar S., Rao D.S., Parfitt A.M. Relationship between osteocyte density and bone formation rate in human cancellous bone. Bone. 31:2002;709-711
9. Ciarelli T.E., Fyhrie D.P., Parfitt A.M. Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone. 32:2003;311-315
10. Martin R.B. Is all cortical bone remodeling initiated by microdamage? Bone. 30:2002;8-13
11. Parfitt A.M. Targeted and non-targeted bone remodeling: relationship to BMU origination and progression. Bone. 30:2002;5-7
12. Parfitt A.M. The bone remodeling compartment: a circulatory function for bone lining cells. J. Bone Miner. Res. 16:2001;1583-1585
13. Parfitt A.M. Misconceptions (2), bone turnover is always higher in cancellous than in cortical bone. Bone. 30:2002;807-809
14. Parfitt A.M. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr. Opin. Nephrol. Hypertens. 12:2003;387-408
15. Eriksen E.F., Langdahl B., Vesterby A., et al. Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women. J. Bone Miner. Res. 14:1999;1217-1221
16. Parfitt A.M., Mathews C.H.E., Villanueva A.R., Kleerekoper M., Frame B., Rao D.S. Relationship between surface, volume and thickness of iliac trabecular bone in aging and in osteoporosis: implications for the microanatomic and cellular mechanism of bone loss. J. Clin. Invest. 72:1983;1396-1409
17. Eriksen E.F. Primary hyperparathyroidism: lessons from bone histomorphometry. J. Bone Miner. Res. 17(Suppl. 2):2002;N95-N97
18. Parfitt A.M. Pathophysiology of bone fragility. Christiansen C., Riis B. Proceedings of the Fourth International Symposium on Osteoporosis, Hong Kong, Handelstrykkeriet Aalborg ApS, Aalborg, Denmark. 1993;164-166
19. Parfitt A.M. High bone turnover is intrinsically harmful: two paths to a similar conclusion. J. Bone Miner. Res. 17:2002;1558-1559
20. Burr D.B., Forwood M.R., Fyhrie D.P., Martin R.B., Schaffler M.B., Turner C.H. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J. Bone Miner. Res. 12:1997;6-15
21. Riggs B.l., Melton L.J. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J. Bone Miner. Res. 17:2002;11-14
22. Phillips A.J., Ostlere S.J., Smith R. Pregnancy-associated osteoporosis: does the skeleton recover? Osteoporos. Int. 11:2000;449-454
23. Heaney R.P. Qualitative factors in osteoporotic fracture: the state of the question. Christiansen C., Johansen J.S., Riis B.J. Osteoporosis. 1987;281-287 Osteo. Press Aps. Copenhagen
24. Weinstein R.S., Powers C.C., Parfitt A.M., Manolagas S.C. Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid-treated mice independently of BMD: an unappreciated determinant of bone strength. J. Bone Miner. Res. 17(Suppl. 1):2002;S156
25. Qiu S., Rao D.S., Palnitkar S., Parfitt A. Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J. Bone Miner. Res. 18:2003;1657-1663
26. Flora L., Hassing G.S., Parfitt A.M., Villanueva A.R. Comparative skeletal effects of two diphosphonates in dogs. Jee W.S.S., Parfitt A.M. Bone Histomorphometry: Third International Workshop. 1981;389-407 Armour Montagu, Paris
27. Parfitt A.M. The two faces of growth: benefits and risks to bone integrity. Osteoporos. Int. 4:1994;382-398
28. Frost H.M. Skeletal structural adaptations to mechanical usage (SATMU):2. Redefining Wolff's law: the remodeling problem. Anat. Rec. 226:1990;414-422
29. Parfitt A.M. Osteoporosis: 50 years of change, mostly in the right direction. Compston J., Ralston S. Osteoporosis and Bone Biology. 2000;1-13 The State of the Art International Medical Press, London